Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses why suppliers must shift from ESG ...

Individual-level attribution modeling reveals that real-world semaglutide effectiveness is not a fixed property of the molecule, but an interaction between pharmacological exposure and modifiable care ...

Raja Shankar, VP of machine learning at IQVIA, discusses which AI capabilities sponsors are most likely to adopt first to streamline trial workflows and reduce operational burden, while also ...

Jeremy Wyatt, CEO, Ametris, discusses how operational best practices for integrating wearables into oncology trials center on minimizing patient burden through thoughtful workflow design, careful ...

Charlie Paterson, partner at PA Consulting, explains how mixed signals on FDA risk tolerance are accelerating the ...

Mike Wenger, chief innovation officer at CRIO, discusses how different site types—from academic medical centers to ...

Miriam Dervan, founder & CEO of mdgroup, explains how treating patient experience as a strategic investment—rather than a ...

Holly Leslie, vice president of services at Ledger Run, explains why site selectivity is not yet universal, but increasingly ...

Charlie Paterson, partner at PA Consulting, outlines how limited FDA guidance on innovative designs, decentralized models, ...

Efficiency and accelerating clinical trial timelines have emerged as key themes at this year’s annual SCOPE Summit in Orlando, FL. The opening keynote panel of the event moderated by Jeremy Goldberg, ...

Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...

Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses how ESG is evolving from a reporting exercise into an auditable measure of operational readiness, and what that ...